In a report published on Thursday morning. The brokerage gave the stock of the biotechnology firm a Hold rating.
Nabriva Therapeutics Stock Price
On Thursday, the stock opened at $1.57. The 50-day moving average of the stock is $1.55, and its 200-day moving average is $1.63. Nabriva Therapeutics's 52-week low is $1.22, and its 52-week high is $8.45. The company's debt-to equity ratio is 0.12; its quick ratio is 0.52 and current ratio 0.85. The last time the company released quarterly earnings was on May 22nd. The biotechnology firm reported ($2.72) in earnings per share for the third quarter. Nabriva Therapeutics reported a negative net profit margin of 148.11%, and a negative equity return of 365.53%. Revenue for the business was $7.59million during the third quarter.
Nabriva Therapeutics: Institutional Trading
Recently, a hedge fund bought a new stake of Nabriva Therapeutics. According to the latest disclosure made by the Securities and Exchange Commission, (SEC), the firm acquired 22,294 shares of the biotechnology company's stock valued at approximately $41,000. The company purchased 22,294 shares in the biotechnology firm, worth approximately $41,000. Susquehanna International Group LLP held approximately 0.07% of Nabriva Therapeutics at the time of its latest SEC filing. Hedge funds and institutional investors own 0.27% of Nabriva Therapeutics.
Get Free Report
Nabriva Therapeutics plc is a biopharmaceutical firm that develops and markets novel anti-infective drugs to treat serious infections. SIVEXTRO is an oxazolidinone class antibacterial used to treat acute bacterial skin infections (ABSSI). XENLETA is a semisynthetic pleuromutilin for oral and intravenous administration.
MarketBeat.com offers a FREE daily email newsletter